SCHEMBL354553

SCHEMBL354553

CCCCNCCCS(=O)(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
ALDH1A1 P00352 1/20 0.52
EPHX2 P34913 1/20 0.46
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
ADH1B P00325 1/20 0.44
ADH1C P00326 1/20 0.44
ADH1A P07327 1/20 0.44
ADH7 P40394 1/20 0.44
CA12 O43570 1/20 0.44
CA7 P43166 1/20 0.44
CA14 Q9ULX7 1/20 0.44
S1PR2 O95136 5/20 0.44
S1PR4 O95977 5/20 0.44
S1PR1 P21453 5/20 0.44
S1PR3 Q99500 5/20 0.44
S1PR5 Q9H228 1/20 0.44
RELA Q04206 4/20 0.43
PAOX Q6QHF9 1/20 0.42
APP P05067 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25298937 0.95 TSHR (0.52) TSHRALDH1A1EPHX2CA1CA2
SCHEMBL917681 0.95 ALDH1A1 (0.59) TSHRALDH1A1EPHX2CA1CA2
SCHEMBL21518429 0.95 TSHR (0.52) TSHRALDH1A1EPHX2CA1CA2
SCHEMBL918208 0.93 ALDH1A1 (0.56) TSHRALDH1A1EPHX2CA1CA2
SCHEMBL918549 0.93 ALDH1A1 (0.56) TSHRALDH1A1EPHX2CA1CA2
SCHEMBL917965 0.93 ALDH1A1 (0.56) TSHRALDH1A1EPHX2CA1CA2
SCHEMBL22800825 0.93 EPHX2 (0.53) TSHRALDH1A1EPHX2CA1CA2
SCHEMBL22800844 0.93 EPHX2 (0.53) TSHRALDH1A1EPHX2CA1CA2
SCHEMBL918712 0.93 ALDH1A1 (0.56) TSHRALDH1A1EPHX2CA1CA2
SCHEMBL917918 0.93 ALDH1A1 (0.56) TSHRALDH1A1EPHX2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12286554-B2 Self-emulsifying polyisocyanate composition, two-pack type coating composition and coating film TOSOH CORPORATION (JP) 2025-04-29 US disclosed
EP-3760657-B1 HYDROPHILIZING AGENT FOR PRODUCTION OF SELF-EMULSIFYING POLYISOCYANATE COMPOSITION, SELF-EMULSIFYING POLYISOCYANATE COMPOSITION, COATING MATERIAL COMPOSITION, AND COATING FILM TOSOH CORP (JP) 2025-04-02 EP disclosed
US-12134677-B2 Hydrophilizing agent for production of self-emulsifying polyisocyanate composition, self-emulsifying polyisocyanate composition, coating material composition, and coating film TOSOH CORPORATION (JP) 2024-11-05 US disclosed
EP-4107198-B1 POLYISOCYANATE PREPARATIONS COVESTRO DEUTSCHLAND AG (DE) 2024-03-13 EP disclosed
WO-2023235985-A1 ZWITTERIONIC COMPOUNDS AND USES THEREOF UNIVERSITY OF SASKATCHEWAN (CA) 2023-12-14 WO disclosed
EP-3560975-B2 IONICALLY HYDROPHILIZED POLYISOCYANATES AND ANTIOXIDANTS COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-12-06 EP disclosed
EP-3724251-B2 IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-11-22 EP disclosed
EP-3851472-B1 IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-06-07 EP disclosed
US-20230080775-A1 POLYISOCYANATE PREPARATIONS COVESTRO DEUTSCHLAND AG (DE) 2023-03-16 US disclosed
CN-110396165-B Ionically hydrophilicized polyisocyanates and antioxidants 科思创德国股份有限公司 2022-12-06 CN disclosed
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BELLUS HEALTH INC. (CA) 2012-01-19 US disclosed
US-8044100-B2 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH INC. (CA) 2011-10-25 US disclosed
US-8044100-B2 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH INC. (CA) 2011-10-25 US disclosed
US-8044100-B2 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH INC. (CA) 2011-10-25 US disclosed
CN-101128421-A Methods and compositions for treating amyloid-related diseases NEUROCHEM INTERNAT LTD (CH) 2008-02-20 CN disclosed
EP-1836161-A2 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES Neurochem (International) Limited (CH) 2007-09-26 EP disclosed
US-20060223855-A1 reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2006-10-05 US disclosed
WO-2006085149-A2 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2006-08-17 WO disclosed
US-4212734-A Inhibiting scale with amino-phosphonic-sulfonic acids PETROLITE CORPORATION (US) 1980-07-15 US disclosed
US-4085134-A ANTISCALING, CORROSION RESISTANCE, CHELATING AGENTS PETROLITE CORPORATION (US) 1978-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223855-A1 reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity APP, IAPP, BACE1 TSHR 4277/4885ALDH1A1 2230/4885EPHX2 2234/4885
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 TSHR 4731/4885ALDH1A1 3131/4885EPHX2 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.